

TCC's ExAblate procedure for cancer treatment

09 July 2014 | News | By BioSpectrum Bureau



Singapore: Taipei Cancer Center (TCC) announced that it would be offering a new non-invasive procedure to treat patients with metastatic bone cancers.

The new technology called ExAblate is a MR guided focused ultrasound (MRgFUS) system, which combines therapeutic acoustic ultrasound waves and continuous guidance and treatment monitoring with an MRI. The procedure is minimally invasive, promising faster recovery and less loss of vital fluids.

The TCC in affiliation with the Taipei Medical University set up its first radiation oncology clinic in Taiwan offering quality treatment to a million cancer patients.

Prof Mr Jeng Fong Chiou, vice superintendent of TCC said, "This treatment provides quick pain relief and is a new breakthrough in cancer treatment. We are very happy to bring it to Taiwan and provide relief to ailing cancer patients."

ExAblate, developed by InSightec ensured a high rate of effectiveness with minimal damage to surrounding tissue.

Dr Roni Yagel, vice president, International markets of InSightec said that TCC joined many other prestigious centers around the world who are now offering patients innovative MR guided focused ultrasound therapy for cancer. He emphasized that adopting this new approach would benefit millions of cancer sufferers in Taiwan.